Literature DB >> 30267256

Increased prescribing of ursodeoxycholic acid in Norway.

Espen Skarstein Kolberg1,2, Morten Tranung3, Kristin Matre Aasarød4.   

Abstract

Background Ursodeoxycholic acid is a hydrophilic bile acid prescribed for a variety of cholestatic liver disorders, although with variable clinical evidence with regards to efficacy. Objective The aim of this study was to investigate the prescription pattern of ursodeoxycholic acid in Norway over the last 13 years. Method Information on the prescribing of ursodeoxycholic acid was extracted from the Norwegian Prescription Database. Data was obtained on the number of individuals who had at least one prescription of ursodeoxycholic acid for any indication dispensed per year in the period 2004-2017. Results The period 2004-2017 witnessed an overall rise in the prevalence of ursodeoxycholic acid prescribing of 237%. With regards to development in prescribing across different age cohorts there is an increase in prescribing in all age groups, although the trend seems to be levelling off in some cohorts. Conclusion Considering the variable clinical evidence of the efficacy of ursodeoxycholic acid, the increase in prescribing is interesting and should prompt vigilance and further research with regards to its long term effects on clinical outcomes.

Entities:  

Keywords:  Norway; Pharmacoepidemiology; Prescription database; Ursodeoxycholic acid

Mesh:

Substances:

Year:  2018        PMID: 30267256     DOI: 10.1007/s11096-018-0729-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  8 in total

1.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

2.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

3.  EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones.

Authors: 
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

Review 4.  Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease.

Authors:  Dominique Debray; Deirdre Kelly; Roderick Houwen; Birgitta Strandvik; Carla Colombo
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

Review 5.  Interventions for treating cholestasis in pregnancy.

Authors:  Vinita Gurung; Philippa Middleton; Stephen J Milan; William Hague; Jim G Thornton
Journal:  Cochrane Database Syst Rev       Date:  2013-06-24

Review 6.  Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Authors:  Katharine Cheng; Deborah Ashby; Rosalind L Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

7.  Comparison of cholecystectomy cases after Roux-en-Y gastric bypass, sleeve gastrectomy, and gastric banding.

Authors:  Rena C Moon; Andre F Teixeira; Christopher DuCoin; Sheila Varnadore; Muhammad A Jawad
Journal:  Surg Obes Relat Dis       Date:  2013-06-04       Impact factor: 4.734

Review 8.  Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Leonardo Henry Eusebi; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.